Compare TFSL & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFSL | ADMA |
|---|---|---|
| Founded | 1938 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.4B |
| IPO Year | 2006 | 2012 |
| Metric | TFSL | ADMA |
|---|---|---|
| Price | $15.16 | $10.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 609.6K | ★ 4.7M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.68% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | 0.08 | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $9.16 | $27.46 |
| Revenue Next Year | $5.22 | $22.11 |
| P/E Ratio | $188.56 | ★ $17.37 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $12.54 | $7.21 |
| 52 Week High | $15.42 | $24.17 |
| Indicator | TFSL | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 41.86 |
| Support Level | $13.16 | $7.21 |
| Resistance Level | $15.42 | $11.42 |
| Average True Range (ATR) | 0.30 | 0.44 |
| MACD | 0.01 | 0.15 |
| Stochastic Oscillator | 69.89 | 23.17 |
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.